This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antibiotic Resistance 2013: The Antibiotics Development Pipeline And Strategies To Combat Antibiotic Resistance

This report identifies 109 candidate antibiotics in the clinical pipeline, approximately 70% of which are in early development (Preclinical and Phase 1). In contrast, there are just 9 candidates at Phase 3, while there are 31 at Phase 2. These pipeline developments are being progressed by 66 companies, of which nine (14%) are major international corporations and 57 (86%) are Small/Medium Sized Enterprises (SMEs).

Executive Summary

Chapter 1 Introduction (p.18)

1.1 Antibiotic Resistance1.2 Resistance Mechanisms1.3 The Resistome1.4 Pathogenomics1.5 Strategies and Targets1.6 The Cost of Antibiotic Resistance1.7 Global Surveillance1.8 This Report

Chapter 2 Antibiotic Resistance, Global Trends (p.27)

2.1 Antibiotic Resistance2.2 Europe2.2.1 Carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2005 to 2010)2.2.2 Escherichia coli 2.2.3 Streptococcus pneumoniae 2.2.4 Staphylococcus aureus 2.2.5 Enterococcus faecalis2.2.6 Klebsiella pneumoniae2.2.7 Pseudomonas aeruginosa2.3 Other Countries2.4 China2.5 USA2.6 Kuwait2.7 Discussion

Chapter 3 Marketed Antibiotics (p.63)

3.1 Marketed Antibiotics3.2 Mechanisms3.3 Companies3.4 Sulphonamides3.5 Beta Lactams (penicillins, cephalosporins, carbapenems, monobactams)3.6 Aminoglycosides3.7 Tetracyclines3.8 Quinolones/Fluoroquinolones3.9 Macrolides3.10 Combinations3.11 Folate antagonists3.12 Mycobacterials3.13 Glycopeptides3.14 Others3.15 Discussion

Chapter 4 Pipeline Antibiotics (p.86)

4.1 Pipeline Antibiotics4.2 Companies4.3 Phase 34.4 Phase 24.5 Phase 14.6 Preclinical4.7 Discussion

Chapter 5 Discussion (p.106)

5.1 Background5.2 Mechanisms5.3 Multiple Activities5.4 Marketed Antibiotics5.5 Antibiotics Pipeline5.6 Circumventing Resistance5.7 Resistance Mutations5.8 Virulence5.9 Conclusions

References (p.120)


Table 2.1 EARSS Surveillance Programme: Countries and Country codes

Table 3.1 Developers or companies with marketed antibiotics for bacterial or fungal

Infections (Source: Biopharm Reports, 2013). The top 11 companies are indicated in blue

Table 3.2 Approved/marketed sulphonamide drugs, which exert their bactericidal effects through folate inhibition (Source: Biopharm Reports, 2013).

Table 3.3 Approved/marketed beta lactam antibiotics, which exert their bactericidal effects through the inhibition of cell wall synthesis (Source: Biopharm Reports, 2013).

Table 3.4 Approved/marketed penicillins, which exert their bactericidal effects through the inhibition of cell wall synthesis (Source: Biopharm Reports, 2013).

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.88 -0.32%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs